Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Elicio Therapeutics (ELTX) Long-Term Investments (2020 - 2023)

Elicio Therapeutics filings provide 4 years of Long-Term Investments readings, the most recent being $150000.0 for Q1 2023.

  • On a quarterly basis, Long-Term Investments fell 79.51% to $150000.0 in Q1 2023 year-over-year; TTM through Mar 2023 was $150000.0, a 79.51% decrease, with the full-year FY2022 number at $874000.0, up 20.89% from a year prior.
  • Long-Term Investments hit $150000.0 in Q1 2023 for Elicio Therapeutics, down from $874000.0 in the prior quarter.
  • In the past five years, Long-Term Investments ranged from a high of $877000.0 in Q1 2021 to a low of $150000.0 in Q1 2023.
  • Median Long-Term Investments over the past 4 years was $852500.0 (2021), compared with a mean of $762200.0.
  • Biggest five-year swings in Long-Term Investments: increased 20.89% in 2022 and later tumbled 79.51% in 2023.
  • Elicio Therapeutics' Long-Term Investments stood at $822000.0 in 2020, then fell by 12.04% to $723000.0 in 2021, then increased by 20.89% to $874000.0 in 2022, then crashed by 82.84% to $150000.0 in 2023.
  • The last three reported values for Long-Term Investments were $150000.0 (Q1 2023), $874000.0 (Q4 2022), and $874000.0 (Q3 2022) per Business Quant data.